Axplora Invests €50 Million in GLP-1 Manufacturing at its French Site
– Axplora is investing €50 million in Mourenx to enhance infrastructure and capabilities.
– The goal is to boost Axplora’s stance in peptide purification within a biologics setting.
– This investment aims to aid the production of innovative therapies, such as GLP-1 drugs for diabetes and obesity.
Author’s Take
Axplora’s substantial investment in its French facility underscores its commitment to advancing peptide purification technology for the development of cutting-edge therapies, particularly in the realm of GLP-1 drugs. This strategic move demonstrates the company’s dedication to staying at the forefront of biologics manufacturing and positioning itself as a key player in the future of healthcare.
Click here for the original article.